While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY／Japan Moves toward Affiliation with PIC/S
April 23, 2007
- COMMENTARY／India Attracts Increasing Attention of Japanese Pharmas
April 16, 2007
- COMMENTARY：Growing Market for Biopharmaceuticals
April 2, 2007
- Japanese Pharma Companies' Licensing Policy: 1 （2） Takeda Pharmaceutical Co., Ltd.
March 26, 2007
- Comentary
March 26, 2007
- Japanese Pharma Companies' Licensing Policy: 1 （1） Takeda Pharmaceutical Co., Ltd.
March 26, 2007
- Future of the Life Sciences Industries: Strategies for Success in 2015
March 19, 2007
- 3 Advantages of Gov't-Private Sector Dialogue Industry Needs to Continuously Present Proposals
February 19, 2007
- Breakthrough Pipelines of Japanese Pharma Companies Keiji Nakamura, Ph. D. Pharma Forum Institute, Kamakura 248-0026
February 12, 2007
- Present and Future of Pharmaceutical Companies in Japan -1- -Prospects for 2001 Analyzed Based on Korosho's Vision for the Pharmaceutical Industry-
January 22, 2007
- Present and Future of Pharmaceutical Companies in Japan -2- -Prospects for 2001 Analyzed Based on Korosho's Vision for the Pharmaceutical Industry-
January 22, 2007
- COMMENTARY 4 articles
December 25, 2006
- Reform Promotion Council to Propose Reference Price System Again
December 11, 2006
- COMMENTARY Major GE Houses Working to Increase Business with Wholesalers
November 13, 2006
- COMMENTARY New Promotion Code to Go into Effect Next January
October 30, 2006
- 70% of People 40 Years or Older Have Pain in Joints, Lower Back: Survey by Stryker
October 23, 2006
- Surveys by JMA, FTC Provide Evidence for Discussions on Generics
October 16, 2006
- COMMENTARY／Original and Generic Makers Should Cooperate for Stable Supply
September 11, 2006
- COMMENTARY Government Increases Efforts to Promote Clinical Research
September 4, 2006
- TOPICS 2 articles
August 28, 2006
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…